Keynote speaker Emmanuelle Charpentier is a French microbiologist, a biochemist, as well as a geneticist. Furthermore, she was the winner of the Chemistry Nobel Prize in 2020, together with Jennifer Doudna. They also co-won the 2020 Wolf Prize in Medicine. These two remarkable women have successfully developed new genome editing techniques.

Following her studies in France, Emmanuelle began an intense scientific career in both Europe and the US. Emmanuelle has spent the majority of her professional career studying disease basic processes. Her research has put a strong emphasis on infections caused by Gram-positive bacterial pathogens, including staphylococci, Listeria, and streptococci.

Emmanuelle has conducted plenty of lab work on the CRISPR-Cas9 acquired immune system in various bacteria. Her research laid the groundwork for the creation of a unique, extremely flexible, and specialized editing and engineering technique for genomes. The CRISPR-Cas technology is transforming life science studies. CRISPR-Cas has created a whole new potential for biotechnologies and biomedical gene therapies, with far-reaching implications for society and mankind. CRISPR-Cas biology and engineering continue to advance at an incredible rate, with fascinating new findings surfacing frequently.

Emmanuelle Charpentier is a speaker who has earned several awards, honors, and doctorate degrees in Asia, North America, and Europe. She and her team’s contributions to the so-called CRISPR-Cas9 discovery led to them receiving numerous awards. Some of Charpentier’s awards include the Breakthrough Prize in Life Sciences, the Gruber Foundation International Prize in Genetic, as well as the Leibniz Prize

Currently, she serves as an elected member of several scientific academies, both internationally and nationally. Emmanuelle is the co-owner and co-inventor of the CRISPR-Cas9 technology’s core intellectual property.

She also co-founded ERS Genomics and CRISPR Therapeutics, together with Shaun Foy and Rodger Novak. Their goal was to develop the CRISPR-Cas technology for genome engineering for use in biotechnological and medicinal applications.